 Galera Therapeutics, Inc. GRTX, a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced the first patient has been dosed in a Phase 2a clinical trial of lead product candidate avasopasem manganese GC4419 to evaluate its ability to reduce the incidence of radiation-induced esophagitis in patients with lung cancer. The open-label, multi-center trial will evaluate the efficacy of avasopasem manganese, a highly selective small molecule superoxide dismutase SOD mimetic, in reducing the incidence of severe Grade 2 or worse on the NCI Common Terminology Criteria for Adverse Events scale acute radiation-induced esophagitis in patients with lung cancer receiving chemoradiotherapy. 